Thromboses and hemorrhages are common in MPN patients with high JAK2V617F allele burden

Area of Science:

• Hematology
• Oncology
• Molecular Biology

Background:

• Myeloproliferative neoplasms (MPN) are associated with life-threatening thrombotic and hemorrhagic events.
• The JAK2V617F mutation is prevalent in MPN, but its correlation with disease progression and complications remains unclear.
• Understanding the role of JAK2V617F allele burden is crucial for risk stratification in MPN.

Purpose of the Study:

• To investigate the relationship between JAK2V617F allele burden and the occurrence of thrombotic and hemorrhagic complications in MPN patients.
• To determine if JAK2V617F allele burden can serve as a predictive marker for adverse outcomes in MPN.

Main Methods:

• A cohort of 253 MPN patients (121 ET, 124 PV, 8 PMF) with available JAK2V617F allele burden data was analyzed.
• Patients were stratified into four quartiles based on their JAK2V617F allele burden (<25%, 26-50%, 51-75%, >75%).
• Incidence of thromboses, hemorrhages, and survival rates were compared across the different quartiles over a median follow-up of 8.8 years.

Main Results:

• A significantly higher incidence of both thrombotic (p=0.001) and hemorrhagic (p<0.001) complications was observed in patients within the higher JAK2V617F allele burden quartiles.
• Patients in the highest quartile (>75% allele burden) exhibited poorer thrombosis- and hemorrhage-free survival.
• These findings highlight a strong association between elevated JAK2V617F allele burden and increased thrombo-hemorrhagic risk.

Conclusions:

• MPN patients with a JAK2V617F allele burden exceeding 75% should be classified as high-risk.
• Elevated JAK2V617F allele burden is a significant predictor of thrombo-hemorrhagic complications in MPN.
• This study underscores the importance of assessing JAK2V617F allele burden for personalized risk management in MPN patients.